RemeGen (HKG:9995) expects 716 million yuan in attributable profit for 2025, which would mark a turnaround from a 1.47 billion yuan loss in 2024, according to a Hong Kong bourse filing Friday.
Shares of the biopharmaceutical company fell nearly 4% in late morning trade on Monday.
Operating revenue for the year is expected to be 3.25 billion yuan, rising 89% year on year from the 1.72 billion yuan generated in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments